TenX Keane Acquisition Shares Rise After Merger Approval

Dow Jones
2024-08-05
 

By Michael Susin

 

TenX Keane Acquisition shares rose on early Monday after its shareholders approved the merger with a subsidiary of Citius Pharmaceuticals.

Shares at were up 18% in recent trading, reaching a record high at $14.55. TenX was one of the few stocks in positive terrain.

The New York-based company said its shareholders voted to approve the combination with the oncology subsidiary of Citius Pharmaceuticals.

The combined company will continue to trade on the Nasdaq stock exchange and is to be renamed Citius Oncology.

The company said the merger is expected to provide Citius Oncology with improved access to equity markets and to support the commercialization of its potential cancer treatment Lymphir, which is currently under biologics license application review.

The merger is expected to be completed in the coming weeks, subject to certain conditions.

 

Write to Michael Susin at michael.susin@wsj.com

 

(END) Dow Jones Newswires

August 05, 2024 10:19 ET (14:19 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10